Skip to main content

Part of UT Health San Antonio

UT Health San Antonio ResearchUT Health San Antonio Research

Research

Part of UT Health San Antonio

Give

Researcher Quicklinks

Institutional Core Labs

  • iLabs
  • Bioanalytics & Single-Cell
  • Biospecimen and Translational Genomics
  • Flow Cytometry
  • Mass Spectometry
  • Optical Imaging
  • Structural Biology (NMR)
  • Structural Biology (X-Ray Crystallography)

Find a Researcher

  • Profiles

Research by School

  • Long School of Medicine
  • School of Dentistry
  • School of Health Professions
  • School of Nursing

Software Training & Cyberinfrastructure

  • VPR IT

Additional Resources

  • Environmental Health & Safety
  • Council of Principal Investigators
  • National Academy of Inventors
  • Office of Technology Commercialization
  • Postdoc Positions
  • Report A Discovery
  • Research Directory
  • San Antonio Bioscience Research
  • San Antonio Partnership for Precision Therapeutics
  • Spotlight on Research Integrity

Close Quicklinks

Menu
  • Home
  • About Us
  • Research Areas
  • Researchers
  • Clinical Trials
  • VPR Resources
  • Collaborations

You are here

  • Stories
  • Academia-Industry Relationships Driving Drug Discovery

Academia-Industry Relationships Driving Drug Discovery

Contributor

March 8, 2019

Chris Green, CPA, met with Josephine A. Taverna, M.D. and Nameer Kirma, Ph.D. to discuss the research sponsored agreement

Research sponsored by academia-industry partnerships are becoming the new normal to drive the development of novel therapeutics.

Rising costs for research and development coupled with a highly competitive funding landscape have prompted researchers to explore other pathways to accelerate biomedical research and improve patient outcomes.

Josephine A. Taverna, M.D., assistant professor of medicine (hematology-oncology) noted that one of her top reasons for joining UT Health San Antonio was the institution’s reputation and strength in drug development. Shortly after her appointment, Dr. Taverna was encouraged to apply to the Mentored Research Career Development Program (KL2), a training and workforce development component of the Clinical and Translational Science Award (CTSA) program. As a KL2 Scholar, Dr. Taverna became eligible for an industry externship through the NCATS-Eli Lilly and Company program at the Eli Lilly headquarters in Indiana.

Grateful for this opportunity, she shared that this experience played a large role in launching her career. “I am fully committed to collaborating with a multidisciplinary team of scientists in both academia and industry to conduct translational research that will make significant impact in the clinic for our cancer patients through biomarker drug discovery.”

Dr. Taverna’s Eli Lilly externship immersed her in an Alzheimer’s disease working group, but she took every opportunity to build relationships with scientists working in oncology and other diseases. After completing her externship, she met with Steven Weitman, M.D. who introduced her to Tolero Pharmaceuticals, Inc. co-founder and chief executive officer, David J. Bearss, Ph.D., (alumnus of cell systems and anatomy). Working with Tolero was a natural fit for Dr. Taverna because the pharmaceutical company’s interests in understanding biomarkers for drug discovery intersected with her own. “In the rapidly changing pharmaceutical world, academic-industry collaboration can make breakthroughs that provide future novel approaches for drug discovery,” said Dr. Bearss, “Dr. Taverna's clinical knowledge and experience with an emerging new technique [CyTOF] has been beneficial identifying potential key biomarkers. We look forward to building this research partnership at my alma mater.”

Dr. Taverna proposed to Tolero’s leadership how the use of the Cytometry by Time of Flight (CyTOF®) instrument in the Bioanalytics and Single-Cell Core Lab (BASiC) would deliver a more robust analysis of key biomarkers for drug development at the single-cell level. Nameer Kirma Ph.D., director of the BASiC Core Lab and associate professor (molecular medicine), provided his expertise regarding the CyTOF® instrument and mass cytometry to Dr. Taverna and the Tolero team. This sponsored research highlights the synergistic relationship and leveraging of resources through academia-industry partnerships.

 

 

Categories:  Research & Innovation; Resources & Services; Training & Funding

The VPR Newsletter

The latest in research discovery, innovation and resources.

Read related stories

  • Dr. Waridibo Allison

    Training the Trainer to Increase Health Care Access

  • History of PTEF

    Announcing the President’s Translational and Entrepreneurial Research Fund 2020 Awards

  • CT Day Collage

    Proyecto Voces (Project Voices): Tu Voz Puede Ayudar a Inmigrantes Latinxs

Share this story

Map image of UT Health San Antonio location

UT Health San Antonio

8403 Floyd Curl Dr
San Antonio, TX 78229

210-567-7000
vpr@uthscsa.edu

Connect with us

  • Twitter
  • YouTube
  • Linked In
  • Facebook
  • Job Opportunities
  • Research Directory
  • Mission Magazine
  • Give a Donation

We make lives better ®

The University of Texas Health Science Center at San Antonio, also called UT Health San Antonio, is a leading academic health center with a mission to make lives better through excellence in advanced academics, life-saving research and comprehensive clinical care including health, dental and cancer services.

Web Privacy | Links from websites affiliated with UT Health's website (uthscsa.edu) to other websites do not constitute or imply university endorsement of those sites, their content, or products and services associated with those sites. The content on this website is intended to be used for informational purposes only. Health information on this site is not meant to be used to diagnose or treat conditions. Consult a health care provider if you are in need of treatment.